ATCC to Use NJ Hospital Samples in Pancreatic Cancer Biomarker Hunt

Nov 02, 2007

NEW YORK (GenomeWeb News) - American Type Culture Collection will use certain genomic technologies to study pancreatic tissue samples collected at a New Jersey Hospital for biomolecules that can be used to help detect, monitor, and potentially treat pancreatic cancer, ATCC said Thursday.

ATCC’s platform consists of integrated genomics, proteomics, and bioinformatics technologies and “has already demonstrated effectiveness in uncovering novel biomarkers for type 2 diabetes,” the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Synthetic Genomics Sued for Gender Discrimination

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Football Team's DNA Day Postponed

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

This Week in Cell

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Featured White Papers

Automated Rare Disease Diagnostics

Sep

27

Featured Webinar

Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep

28

Featured Webinar

Clinical Utility of Comprehensive and Fast Genomic Interpretation

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.

Main menu